Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin vs Heparin in AMI Patients Undergoing PCI
NCT02897037Phase 3Unknown
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Nov 2016
- Primary completion
- Jun 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of bivalirudin in acute myocardial infarction (AMI) (2 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Net Adverse Clinical Events at 30 days. Status: unknown.
02
Drugs
bivalirudin
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT02897037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897037.